Patents by Inventor Donald A. McLeod

Donald A. McLeod has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220240661
    Abstract: A toothbrush apparatus, a method, and a medical system. The apparatus includes a sensing module configured to detect one or more brushing parameters for determining at least a brushing intensity. One or more processors are communicatively coupled to the sensing module and are configured to determine at least the brushing intensity and output the determined brushing intensity.
    Type: Application
    Filed: April 25, 2022
    Publication date: August 4, 2022
    Inventors: William Thomas MAY, Simon ENEVER, Paul KOH, John DEY, Zachary ZARO, Andrew MCLEOD, Fernando D. PAREDES, Donald J. DEFICCIO, II, William M. SAKRAN
  • Publication number: 20150352108
    Abstract: The invention relates to certain amino-pyrimidine compounds which inhibit TBK1 and/or IKK epsilon and which may therefore find application in treating inflammation, cancer, septic shock and/or Primary open Angle Glaucoma (POAG).
    Type: Application
    Filed: December 23, 2014
    Publication date: December 10, 2015
    Applicant: Alzheimer's Institute of America
    Inventors: Ryan C. Holcomb, Kazuyuki Suzuki, Robert J. Halter, Paul R. Sebahar, Donald A. McLeod, Mark D. Shenderovich, Kraig M. Yager, Matthew Gregory Bursavich, Ashantai J. Yungai, Burt Richards, Paul L. Bartel, Daniel A. Wettstein
  • Publication number: 20140288044
    Abstract: The invention relates to compounds, pharmaceutical compositions and medicaments comprising such compounds, and the use of these compounds, compositions, and medicaments in methods of treating diseases and disorders.
    Type: Application
    Filed: April 12, 2012
    Publication date: September 25, 2014
    Applicant: Alzheimer's Institute of America, Inc.
    Inventors: Ryan Holcomb, Paul R. Sebahar, Kazuyuki Suzuki, Donald A. McLeod, David M. Dastrup, Christophe Hoarau, Robert J. Halter, Matthew Gregory Bursavich, Mark D. Shenderovich, Burt Richards, Paul L. Bartel
  • Patent number: 8480758
    Abstract: An assembly for fixating a prosthesis in body tissue such as bone of a mammal, comprising a mechanical compacting device and a mass comprising at least granules of a biocompatible material having a sponge-like structure, wherein the mechanical compacting device is designed for compacting the granules during use by insertion of the device in a hole in bone and subsequently inducing relative movement of at least a first part of the compacting device relative to a second part thereof, such that the volume of at least one space between at least part of an outer surface of the device and the adjacent inner surface of said hole is reduced.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: July 9, 2013
    Assignee: Fondel Finance, B.V.
    Inventor: Daniel John Donald McLeod
  • Publication number: 20120238540
    Abstract: The invention relates to certain amino-pyrimidine compounds that inhibit IKK epsilon and/or TBK1, methods of making such compounds, pharmaceutical compositions comprising such compounds, and the use of these compounds in treating a variety of diseases and disorders.
    Type: Application
    Filed: April 12, 2012
    Publication date: September 20, 2012
    Applicant: Myrexis, Inc.
    Inventors: Ryan C. HOLCOMB, Kazuyuki Suzuki, Robert J. Halter, Paul R. Sebahar, Donald A. McLeod, Mark D. Shenderovich, Kraig M. Yager, Matthew Gregory Bursavich, Ashantai J. Yungai, Burt Richards, Paul L. Bartel, Daniel A. Wettstein
  • Patent number: 7960422
    Abstract: Compounds of formula (I) wherein R1 is as well as pharmaceutically acceptable salts, hydrates and/or enantiomers thereof are useful as compounds that exhibit activity at metabotropic glutamate receptors.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: June 14, 2011
    Assignee: AstraZeneca AB
    Inventors: Erwan Arzel, Louise Edwards, Methvin Isaac, Donald A. McLeod, Abdelmalik Slassi, Tao Xin
  • Patent number: 7691892
    Abstract: The present invention relates to new compounds of formula I, wherein P, Q, X1, X2, X3, X4, R1, R2, m and p, are as defined as in formula I, or, salts, solvates or solvated salts thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: April 6, 2010
    Assignee: AstraZeneca AB
    Inventors: Martin Johansson, Alexander Minidis, Karin Staaf, David Wensbo, Donald McLeod, Louise Edwards, Methvin Isaac, Anne O'Brien, Abdelmalik Slassi, Tao Xin, Tomislav Stefanac
  • Patent number: 7585881
    Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: September 8, 2009
    Assignee: AstraZeneca AB
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tau Xin, Jalaj Arora
  • Publication number: 20090131454
    Abstract: The present invention is directed to novel compounds, their use in therapy and pharmaceutical compositions comprising said novel compounds.
    Type: Application
    Filed: October 17, 2008
    Publication date: May 21, 2009
    Applicant: AstraZeneca AB
    Inventors: Erwan Arzel, Louise Edwards, Methvin Isaac, Donald A. McLeod, Abdelmalik Slassi, Tao Xin
  • Publication number: 20080312246
    Abstract: The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar1, Ar2, Hy, L, R1, m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses thereof, processes for making the compounds, as well as methods for the medical treatment of mGluR5-mediated disorders.
    Type: Application
    Filed: August 4, 2006
    Publication date: December 18, 2008
    Applicant: AstraZeneca AB
    Inventors: Louise Edwards, Abdelmalik Slassi, Methvin Isaac, Donald Mcleod, Tao Xin
  • Patent number: 7456200
    Abstract: The present invention relates to new compounds of formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing compounds of the formula I and to the use of compounds of the formula I in therapy.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: November 25, 2008
    Assignee: Astrazeneca AB
    Inventors: Jalaj Arora, Louise Edwards, Methvin Isaac, Donald A. McLeod, Abdelmalik Slassi, Tomislav Stefanac, Thomas M. Stormann, David Wensbo, Tao Xin, Helena Gyback, Martin Johansson, Annika Kers, John Malmberg, Alexander Minidis, Karin Oscarsson, Mangus Waldman, Ulrika Yngve, Christoffer Osterwall
  • Publication number: 20080228269
    Abstract: Embodiments are directed to moulded article, provided with granules made of a bio-compatible material, which granules have a substantially porous structure and are interconnected, forming a rigid or semi-rigid structure; a mass for forming such a moulded article; and a method for forming a moulded article, comprising the steps of providing a mass comprising at least granules made of a bio-compatible material and having a porous structure, and pressing said mass, especially said granules together, for forming a rigid or semi-rigid structure.
    Type: Application
    Filed: November 9, 2007
    Publication date: September 18, 2008
    Applicant: Fondel Finance B.V.
    Inventors: Allan Gordon McLeod, Daniel John Donald McLeod
  • Publication number: 20080045571
    Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Application
    Filed: August 18, 2007
    Publication date: February 21, 2008
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS INC.
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora
  • Publication number: 20080015204
    Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Application
    Filed: August 18, 2007
    Publication date: January 17, 2008
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS INC.
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora
  • Publication number: 20080015234
    Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Application
    Filed: August 18, 2007
    Publication date: January 17, 2008
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS INC.
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora
  • Publication number: 20070293545
    Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Application
    Filed: August 18, 2007
    Publication date: December 20, 2007
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS INC.
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora
  • Publication number: 20070255061
    Abstract: The present invention relates to new compounds of formula I, wherein Z, Q, X1, X2, R1 and R2, are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: December 13, 2004
    Publication date: November 1, 2007
    Applicants: AstraZeneca AB, NPS Pharmaceuticals, Inc.
    Inventors: David Wensbo, Louise Edwards, Methvin Isaac, Donald McLeod, Abdelmalik Slassi, Tao Xin, Thomas Stormann
  • Publication number: 20070197549
    Abstract: The present invention relates to new compounds of formula I, wherein P, Q, X1, X2, X3, X4, R1, R2, m and p, are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds, and to the use of said compounds in therapy.
    Type: Application
    Filed: February 17, 2005
    Publication date: August 23, 2007
    Applicant: AstraZeneca AB
    Inventors: Martin Johansson, Alexander Minidis, Karin Staaf, David Wensbo, Donald McLeod, Louise Edwards, Methvin Isaac, Anne O'Brien, Abdelmalik Slassi, Tao Xin, Tomislav Stefanac
  • Publication number: 20070185095
    Abstract: The present invention is directed to compounds of formula: (I); wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, R1, R2, R3, R4, and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds for treating gastrointestinal disorders.
    Type: Application
    Filed: February 17, 2005
    Publication date: August 9, 2007
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS, INC.
    Inventors: Martin Johansson, David Wensbo, Alexander Minidis, Karin Staaf, Annika Kers, Louise Edwards, Methvin Isaac, Tomislav Stefanac, Abdelmalik Slassi, Donald McLeod, Tao Xin
  • Publication number: 20070179188
    Abstract: The present invention relates to new compounds of formula (I), to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Application
    Filed: February 15, 2005
    Publication date: August 2, 2007
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS, INC.
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald Mcleod, Alexander Minidis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora